# Cannabis News and Regulatory Roundup: Cannabis Use and Breastfeeding Initiation: A… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-cannabis-use-and-breastfeeding-init-sep-2026/ > **Published:** 2026-09-17T19:26:03-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:28-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic This curated cannabis news and regulatory roundup delivers practical physician analysis of 3 timely developments across cannabis policy, administrative rulemaking, and consumer health protections. By evaluating these updates within their specific regulatory and clinical contexts, healthcare providers and registered patients can separate genuine progress from speculative marketing claims. Staying informed about laboratory testing standards, licensing rules, and emerging data ensures that clinical counseling remains grounded in verified evidence, prioritizing patient safety and therapeutic efficacy above all. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Cannabis Use and Breastfeeding Initiation: Associa. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42753239/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us A study examining breastfeeding initiation among perinatal cannabis users found that initiation rates were highest (89.52%) among those using cannabis postpartum only, while those using both prenatal and postpartum had the lowest rates (71.88%). Additionally, women advised against cannabis use while breastfeeding had significantly lower initiation rates (81.95%) compared to those who were not advised (94.07%). In a separate investigation, computational modeling identified 20 novel cannabis-derived compounds with enhanced antiproliferative activity against colorectal cancer, with specific compounds showing strong binding affinity to CDK2, a key target in cancer therapy. Why This Matters These findings highlight the critical role of clinician counseling on cannabis use during breastfeeding, which may directly influence breastfeeding rates. Furthermore, the identification of novel cannabis-derived compounds could pave the way for new therapeutic options in colorectal cancer treatment, impacting clinical practice and patient outcomes. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 17, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Cannabis Use and Breastfeeding Initiatio (Skelton et al., PubMed) [DOI: 10.1177/15568253261490303 | PMID: 42753239]Study 2Cannabis as a source of novel therapeuti (Allah et al., PubMed) [DOI: 10.1016/j.jgeb.2026.100763 | PMID: 42749433]Study 3Cannabis Commercialization as a Modifiab (Gilman et al., PubMed) [DOI: 10.1001/jamapsychiatry.2026.2869 | PMID: 42747827] Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Cannabis Use and Breastfeeding Initiation: Associa](#digest-card-2-digest-card-1-cannabis-use-and-breastfeeding-initiation-associa) - [Digest Card 2 | Cannabis as a source of novel therapeutics: A comp](#digest-card-3-digest-card-2-cannabis-as-a-source-of-novel-therapeutics-a-comp) - [Digest Card 3 | Cannabis Commercialization as a Modifiable Public](#digest-card-4-digest-card-3-cannabis-commercialization-as-a-modifiable-public) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Cannabis Use and Breastfeeding Initiation: Associa **Title & Source:** [Cannabis Use and Breastfeeding Initiation: Associations with Patterns, Perceived Risk, and Clinical Advice in a Multistate Pregnancy Risk Assessment Monitoring System Study (2017-2021).](https://pubmed.ncbi.nlm.nih.gov/42753239/) (*PubMed*, 2026Sep17) **Lead Authors & Identifiers:** Kara R Skelton, Stacey E Iobst, Sara E Benjamin-Neelon. | **Primary Record:** DOI: 10.1177/15568253261490303 | PMID: 42753239 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** In this evaluation by Skelton and colleagues, Despite increasing prevalence of perinatal cannabis use, little is known about how advice about cannabis use while breastfeeding at prenatal care visits is associated with breastfeeding initiation. We examined whether breastfeeding initiation varied by (1) maternal safety perceptions of cannabis use while breastfeeding, (2) perinatal cannabis use patterns, and (3) receipt of prenatal counseling regarding cannabis use. In this repeated cross-sectional study, we used 2017-2021 Pregnancy Risk Assessment Monitoring System data for 10 states that used the Marijuana Supplement. We further restricted the analytic sample to those respondents who reported any perinatal cannabis use. We calculated weighted prevalence estimates and used survey-weighted chi-square tests to assess differences in breastfeeding initiation by cannabis use pattern (prenatal only, postpartum only, or both), perceived safety of cannabis use while breastfeeding, and receipt of prenatal advice not to breastfeed if using cannabis. In the analytic sample (N = 52,577 live births), breastfeeding initiation was highest among those who reported postpartum-only cannabis use (89.52%; 95% CI: 82.01, 94.12) and lowest among those reporting both prenatal and postpartum cannabis use (71.88%, 95% CI: 63.25, 79.16). Breastfeeding initiation differed significantly by receipt of advice among women reporting postpartum-only cannabis use, with lower initiation among women who were advised against cannabis use while breastfeeding in comparison with those who were not advised (81.95% versus 94.07%; p = 0.004). Our findings underscore the importance of clinician counseling about cannabis use while breastfeeding. Future studies should examine communication strategies to discourage cannabis use while breastfeeding while simultaneously promoting breastfeeding as the best infant feeding choice. Understanding this publication requires placing it within the broader framework of administrative implementation, market dynamics, and regulatory policy. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** In the study by Skelton et al., which analyzed data from 52,577 live births, breastfeeding initiation was significantly associated with cannabis use patterns. Specifically, postpartum-only cannabis users had an initiation rate of 89.52% (95% CI: 82.01, 94.12), while those using cannabis both prenatally and postpartum had a lower initiation rate of 71.88% (95% CI: 63.25, 79.16). The study also found that women advised against cannabis use while breastfeeding had a lower initiation rate (81.95%) compared to those not advised (94.07%; p = 0.004). **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. Patients and healthcare operators navigating evolving regulations benefit from focusing on product testing transparency, verified licensing, and patient protections. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all rapidly evolving administrative updates and news reports, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. Digest Card 2 | Cannabis as a source of novel therapeutics: A comp **Title & Source:** [Cannabis as a source of novel therapeutics: A computational study combining LBDD and structure-based docking/dynamics to identify novel drug-like compounds for colorectal cancer.](https://pubmed.ncbi.nlm.nih.gov/42749433/) (*PubMed*, 2026Sep) **Lead Authors & Identifiers:** Khadija Khaddam Allah, Khaoula Mkhayar, Rachid Haloui, Amine Ballari, Ossama Daoui, Kaouakeb El Khattabi, Abdelmoula El Abbouchi, Samir Chtita, Souad El Khattabi. | **Primary Record:** DOI: 10.1016/j.jgeb.2026.100763 | PMID: 42749433 Content lane: **Mechanism Watch**. **1. Scientific & Clinical Background:** In this evaluation by Allah and colleagues, Cannabis represents a valuable source of bioactive compounds with significant therapeutic potential, thanks to its rich phytochemical profile, making it a prime candidate for cancer research. Our study investigates the potential of cannabis-derived compounds to inhibit cyclin-dependent kinase 2 (CDK2), a crucial regulator of cell-cycle progression and colorectal cancer cell proliferation. A comprehensive computational workflow integrating 3D-QSAR modeling, molecular docking, molecular dynamics simulations, drug-likeness assessment, and ADMET prediction was employed to investigate a dataset of 33 cannabis-derived compounds. The robustness and predictive performance of the generated CoMFA and CoMSIA models were confirmed through internal and external validation, leave-one-out cross-validation (LOOCV), and Y-randomization tests, yielding excellent statistical parameters for CoMFA (Q2=0.651, R2=0.986, SEE=0.069) and CoMSIA (Q2=0.665, R2=0.985, SEE=0.071). Using contour map analysis, twenty new molecules (V1-V20) with enhanced antiproliferative activity against the HCT-116 colorectal cancer cell line were developed, and outperformed the original dataset’s most active one. Following drug-likeness screening and ADMET profiling, compounds V2, V5, V7, and V8 emerged as the most promising candidates, exhibiting favorable pharmacokinetic properties and drug-like characteristics. Molecular docking studies revealed that V7 and V8 exhibit high stability within the CDK2 active site and possess stronger binding affinity than the reference compound. Furthermore, 100 ns molecular dynamics simulations demonstrated that both protein-ligand complexes reached stable conformational states, as confirmed by converged backbone RMSD profiles, low residue fluctuations (RMSF), persistent protein-ligand interactions, and complementary structural descriptors including radius of gyration (Rg), solvent-accessible surface area (SASA), and molecular surface area (MolSA). Collectively, these analyses confirmed the structural stability and compactness of the investigated complexes throughout the simulation period, with V8 exhibiting the most favorable dynamic behavior. Understanding this publication requires placing it within the broader framework of administrative implementation, market dynamics, and regulatory policy. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** Allah et al. conducted a computational study involving 33 cannabis-derived compounds to evaluate their potential as inhibitors of cyclin-dependent kinase 2 (CDK2) in colorectal cancer. The study achieved excellent predictive performance with CoMFA (Q2=0.651, R2=0.986) and CoMSIA (Q2=0.665, R2=0.985) models. Notably, compounds V7 and V8 demonstrated high stability and stronger binding affinity within the CDK2 active site compared to the reference compound, indicating their potential as therapeutic agents. **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. Patients and healthcare operators navigating evolving regulations benefit from focusing on product testing transparency, verified licensing, and patient protections. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all rapidly evolving administrative updates and news reports, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. Digest Card 3 | Cannabis Commercialization as a Modifiable Public **Title & Source:** [Cannabis Commercialization as a Modifiable Public Health Exposure.](https://pubmed.ncbi.nlm.nih.gov/42747827/) (*PubMed*, 2026Sep16) **Lead Authors & Identifiers:** Jodi M Gilman, Cheryl Y S Foo, Andrew S Hyatt, A Eden Evins. | **Primary Record:** DOI: 10.1001/jamapsychiatry.2026.2869 | PMID: 42747827 Content lane: **Research Brief**. **1. Scientific & Clinical Background:** In this evaluation by Gilman and colleagues, This Viewpoint describes how policies shaping cannabis commercialization constitute a modifiable exposure and, thus, may influence psychiatric risk and suggests mitigation strategies. Understanding this publication requires placing it within the broader framework of administrative implementation, market dynamics, and regulatory policy. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** Gilman et al. presented a viewpoint on cannabis commercialization, suggesting that policies governing this area represent a modifiable public health exposure that could influence psychiatric risk. The authors propose that understanding and adjusting these policies may mitigate potential psychiatric risks associated with cannabis use. The commentary emphasizes the need for ongoing evaluation of the implications of cannabis commercialization on public health. **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. Patients and healthcare operators navigating evolving regulations benefit from focusing on product testing transparency, verified licensing, and patient protections. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all rapidly evolving administrative updates and news reports, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. How Strong Is This Evidence? The strongest clinical signal here comes from PMID 42753239, a repeated cross-sectional analysis of 2017 to 2021 Pregnancy Risk Assessment Monitoring System data examining breastfeeding initiation in relation to perinatal cannabis use, perceived safety, and prenatal counseling. Because it uses a multistate population dataset and evaluates real-world counseling exposure, it can describe associations at scale, but it remains observational rather than causal. PMID 42747827 is a computational drug-discovery study, and PMID 42749433 is also preclinical and in silico, so neither provides human efficacy or safety evidence for patient care. Where This Paper Deserves Skepticism The breastfeeding study is vulnerable to self-report bias for cannabis use, perceived risk, and counseling, and residual confounding is likely because breastfeeding initiation is strongly shaped by socioeconomic factors, tobacco or alcohol use, mental health, parity, and access to lactation support. Cross-sectional measurement also limits temporal inference, so it is not possible to know whether counseling changed behavior or whether patients with different baseline intentions were simply counseled differently. The cancer and colorectal cancer papers are hypothesis-generating only, with docking and molecular dynamics unable to establish biologic activity in humans, dose, bioavailability, or clinical benefit. What This Paper Does Not Show These studies do not prove that cannabis use during breastfeeding causes lower breastfeeding initiation, or that prenatal counseling alone will reliably change breastfeeding outcomes. They also do not establish any FDA-approved indication for cannabis in lactation, pregnancy, or cancer treatment, and the computational oncology papers do not show that cannabis-derived compounds treat colorectal cancer in patients. How This Fits With the Broader Clinical Conversation Taken together, these papers reflect two very different research tracks, one focused on population-level maternal health behavior and one on early-stage compound discovery, with only the former directly relevant to bedside counseling today. For clinicians, the practical issue is not whether cannabis has theoretical pharmacology, but whether current evidence supports safer breastfeeding decisions, clearer prenatal counseling, and avoidance of overinterpreting preclinical anticancer claims. Dr. Caplan’s Take *In prenatal care, the most actionable finding is that breastfeeding initiation appears to vary with how patients perceive cannabis risk and whether they receive counseling about cannabis use while breastfeeding. That means the clinical conversation matters, but this study cannot tell us the best counseling script or prove that counseling alone changes outcomes. I would use it to prompt direct, nonjudgmental discussion of cannabis exposure, breastfeeding goals, and other modifiable supports such as lactation consultation, tobacco cessation, and mental health care.* *The oncology papers are useful only as early signal generation. A docking model against CDK2 and a computational search for drug-like compounds do not justify recommending cannabis products for colorectal cancer, and they do not substitute for pharmacokinetic, toxicology, or randomized human data. Patients should not interpret these findings as evidence that cannabis treats cancer, and clinicians should keep recommendations anchored to established cancer therapy and symptom-directed supportive care.* What a Careful Reader Should Take Away The breastfeeding study suggests counseling and risk perception are associated with breastfeeding initiation, but it does not prove causation. The cancer-related papers are preclinical and computational only, so they should be viewed as hypothesis-generating rather than practice-changing. Evidence Interpretation Guide Table of Contents - [How to Interpret This Research Update](#How_to_Interpret_This_Research_Update)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Focus on Practical Realities and Safe Access](#Focus_on_Practical_Realities_and_Safe_Access) - [Incorporate Policy and Research Context Into Patient Counseling](#Incorporate_Policy_and_Research_Context_Into_Patient_Counseling) - [Prioritize Tested Products and Clear Labeling Standards](#Prioritize_Tested_Products_and_Clear_Labeling_Standards) - [Track Administrative Implementation Details Closely](#Track_Administrative_Implementation_Details_Closely) - [Demand Controlled Methodologies and Prospective Data](#Demand_Controlled_Methodologies_and_Prospective_Data) - [Separate Promotional Announcements from Verified Evidence](#Separate_Promotional_Announcements_from_Verified_Evidence) - [Maintain Safe Boundaries and Transparent Communication](#Maintain_Safe_Boundaries_and_Transparent_Communication) - [A Calibrated and Evidence-Grounded Perspective](#A_Calibrated_and_Evidence-Grounded_Perspective) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Research Update This set of studies spans a population-based maternal health analysis and two early-stage computational oncology papers, so the clinical relevance is very different across the articles. ### Three Rules for Critical Reading **1. Match the study design to the claim**PMID 42753239 can identify associations in a multistate PRAMS sample from 2017 to 2021, but it cannot prove that cannabis counseling changes breastfeeding initiation. PMID 42747827 and PMID 42749433 are computational studies, so they can suggest molecular targets such as CDK2, but they cannot establish patient benefit. **2. Look for the hidden confounders**Breastfeeding initiation is influenced by parity, race and ethnicity, income, tobacco use, alcohol use, mental health, and access to lactation support, all of which can distort observed cannabis associations. Self-reported cannabis use, perceived safety, and counseling also introduce recall and social desirability bias. **3. Separate biologic plausibility from clinical proof**Docking scores, molecular dynamics, and 3D-QSAR can prioritize compounds, but they do not show absorption, metabolism, toxicity, or efficacy in humans. For patients, the only clinically actionable evidence here is the observational breastfeeding study, and even that supports discussion, not a treatment recommendation. Key Evaluation QuestionDo these data show a causal effect of prenatal cannabis counseling on breastfeeding initiation, or only an association that may be explained by baseline differences in patient characteristics and care access? The Patient QuestionIf I use cannabis during pregnancy or while breastfeeding, what does the current evidence actually say about breastfeeding, infant exposure, and safer alternatives for symptom control? The Bottom LineThese papers support careful counseling and cautious interpretation, but they do not justify cannabis as a breastfeeding aid or a cancer treatment. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight perspectives on emerging cannabis policy, science, and clinical practice. #### Focus on Practical Realities and Safe Access Patients evaluating these developments should recognize that policy changes and scientific reports describe broader systemic movements rather than immediate personal treatment plans. Staying informed through official state dockets and peer-reviewed journals helps separate genuine clinical options from premature commercial hype and exaggerated marketing claims. Understanding the specific rules governing product labeling, dispensary availability, and testing standards ensures that patients make safe, legally protected healthcare choices. Always discuss new cannabinoid products or dosing questions with a knowledgeable certifying physician before making substantial treatment changes. Lens takeawayVerified healthcare information empowers patients to make grounded and safe medical decisions every single day. #### Incorporate Policy and Research Context Into Patient Counseling Healthcare providers benefit from tracking regulatory shifts and emerging literature because patient questions frequently mirror breaking news. When patients inquire about new state programs, novel product categories, or early clinical trials, clinicians who understand the underlying data can provide calm, evidence-informed guidance. Maintaining an active dialogue about product purity, cannabinoid ratios, and potential medication interactions strengthens the therapeutic relationship. Clinical counseling improves when providers ground their recommendations in verified primary evidence rather than generic assumptions or unverified third-party claims. Lens takeawayContextual awareness of evolving policies and clinical evidence substantially enhances the quality of routine patient care. #### Prioritize Tested Products and Clear Labeling Standards Product safety remains the central foundation of effective cannabinoid medicine. Rigorous laboratory testing for heavy metals, pesticides, residual solvents, and microbial contaminants protects vulnerable patients from avoidable harms. Mislabeled or unregulated formulations present ongoing public-health challenges across many regional markets. Standardized packaging, accurate milligram labeling, and child-resistant containers are essential safeguards that deserve universal enforcement. Clinicians and consumers must continue advocating for uncompromising quality assurance and transparent certificate of analysis access across all regulated state programs. Lens takeawayUncompromising testing standards and transparent product labeling are fundamental prerequisites for legitimate patient safety. #### Track Administrative Implementation Details Closely Legislative enactments and administrative dockets represent initial milestones in a lengthy implementation lifecycle. Rulemaking processes, licensing timelines, and municipal zoning decisions determine how policy directives translate into real-world patient access across different local communities. Monitoring regulatory agencies as they refine testing protocols and fee structures helps stakeholders anticipate market adjustments. Clear, predictable administrative frameworks provide long-term stability for both registered patients and compliant healthcare operators navigating regional markets. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayEffective implementation and transparent administrative oversight govern the real-world success of any progressive healthcare policy. #### Demand Controlled Methodologies and Prospective Data Preliminary observations and retrospective surveys generate valuable hypotheses but cannot replace randomized, controlled clinical investigations. Advancing cannabinoid therapeutics requires well-funded, methodologically rigorous studies with standardized dosing formulations and validated objective endpoints. Expanding public research funding and removing regulatory barriers to clinical trials will accelerate our understanding of the endocannabinoid system. Rigorous scientific inquiry remains the indispensable gold standard for clinical validation and evidence-informed medical guidance. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayMethodologically rigorous prospective investigations are essential to convert preliminary scientific signals into established clinical practice. #### Separate Promotional Announcements from Verified Evidence A disciplined medical reading requires separating commercial marketing from verified scientific data. Industry press releases often highlight positive associations while downplaying methodological limitations, small sample sizes, or short follow-up durations across preliminary investigations. Applying consistent critical appraisal protects clinicians and consumers from adopting premature conclusions. Genuine therapeutic progress is demonstrated through reproducible evidence rather than optimistic corporate forecasts or speculative public announcements. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayRigorous critical skepticism protects both clinicians and patients from confusing promotional marketing with reproducible evidence. #### Maintain Safe Boundaries and Transparent Communication Family members and caregivers supporting patients who use medical cannabis require clear, practical instructions on product storage, administration schedules, and emergency precautions. Keeping products securely locked away in designated containers prevents accidental pediatric or household exposures. Open communication among family members, caregivers, and certifying physicians fosters a supportive environment that enhances treatment adherence. Clear boundaries and designated storage routines ensure household safety while supporting patient wellness throughout their therapeutic journey. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawaySecure product storage and transparent family communication establish a safe, supportive environment for medical cannabis care. #### A Calibrated and Evidence-Grounded Perspective Progress across cannabinoid therapeutics and public policy occurs through steady, incremental milestones rather than sudden breakthroughs. Synthesizing multiple developments into a cohesive overview provides a balanced, realistic picture of current industry and clinical trends. Keeping expectations grounded in verifiable facts enables clinicians, regulators, and patients to make informed decisions that promote long-term well-being. CED Clinic remains dedicated to delivering objective, physician-guided education across every single phase of patient care. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayGrounded understanding and rigorous evaluation of verified facts serve the long-term interests of patients and clinicians. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Cannabis+Use+and+Breastfeeding+Initiation%3A+A...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-breastfeeding-init-sep-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-breastfeeding-init-sep-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Cannabis+Use+and+Breastfeeding+Initiation%3A+A...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-breastfeeding-init-sep-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: PubMed, PubMed, PubMed](https://pubmed.ncbi.nlm.nih.gov/42753239/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Care](https://cedclinic.com/drcaplan/) Dr. Caplan’s physician-led clinical practice and comprehensive patient guidance. [Learn about CED Clinic](https://cedclinic.com/drcaplan/)[Cannabis Research Library](https://cedclinic.com/category/cannabis-science/) Rigorous physician analysis of peer-reviewed cannabinoid literature and clinical trials. [Explore the research](https://cedclinic.com/category/cannabis-science/)[Cannabis News and Regulatory Updates](https://cedclinic.com/category/cannabis-news/) In-depth physician coverage of legal and regulatory developments in cannabis. [Read news updates](https://cedclinic.com/category/cannabis-news/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).